Importantly, our results are in agreement with a recent report from the Biomarker Study Group, where a 1:1250 MOG autoantibody titer cutoff showed better specificity than a 1:160 cutoff for prediction of a non-MS course in a pediatric population (59). This evidence concerns the gene MOG and myeloid sarcoma.